European Commission approves the first single-use intramuscular
autoinjector designed to improve convenience of once-weekly AVONEX
(interferon beta-1a) administration
Jun. 7, 2011 (Business Wire) -- Third paragraph, first sentence should read: ....AVONEX 30mcg/0.5ml... (sted ...AVONEX 30mcg/50ml...)
The corrected release reads:
Biogen Idec Receives Approval in the European Union for AVONEX® PEN™
European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration
Biogen Idec (NASDAQ: BIIB) announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.
"At Biogen Idec, our commitment to the MS community is unwavering. We strive to meet the needs of all MS patients by harnessing our extensive expertise in neurology and through our commitment to research and innovation," said Douglas E. Williams, Ph.D., Executive Vice President, Research and Development at Biogen Idec. "For more than 10 years, AVONEX has been the therapy of choice for many MS patients who prefer the convenience of once-weekly injections, along with its proven efficacy and a well-established safety profile. Not only do we think AVONEX PEN makes AVONEX therapy more convenient, it can also help alleviate the anxiety that some MS patients feel when they have to inject their medication."
AVONEX PEN (AVONEX 30mcg/0.5ml solution for injection, in pre-filled pen) is the first single-use, once-a-week, fully integrated intramuscular autoinjector available for use with AVONEX treatment in patients with relapsing MS. Biogen Idec designed AVONEX PEN to improve convenience of AVONEX administration by simplifying the injection, helping to reduce injection anxiety and supporting patient independence. It integrates the currently approved AVONEX Prefilled Syringe and utilizes a 25 gauge 16 mm (5/8 inch) needle. This needle was specifically created for AVONEX PEN to be shorter than the needle in the AVONEX Prefilled Syringe.
Additional features of AVONEX PEN include a protective injector shield that conceals the needle prior to injection, automated needle insertion and medication delivery, and a diameter and length designed to stabilize AVONEX PEN during the injection procedure. In addition, AVONEX PEN incorporates a safety lock, which helps prevent injection error, and a display window that confirms complete delivery of the medication. The approval by the EC is based, in part, on a Phase 3b open-label, multicenter study which evaluated the safety and efficacy of AVONEX PEN.